Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.91 below Bioaffinity Technologies Inc 's average Quick Ratio.

Within Medical Laboratories industry 22 other companies have achieved higher Quick Ratio than Bioaffinity Technologies Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1560 to 1899.

Explain Quick Ratio?
How much Cash & cash equivalents BIAF�s has?
What are BIAF�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BIAF Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	3.58 %	-6.75 %	-6.4 %	-5.28 %	11.26 %
Y / Y Cash & cash equivalent Change	202.64 %	596.72 %	483.54 %	913.67 %	0.19 %
Quick Ratio MRQ	0.91	0.97	2.22	3.25	0.31
BIAF's Total Ranking	# 1899	# 1560	# 1044	# 694	# 2316
Seq. Current Liabilities Change	-15.83 %	9.59 %	23.16 %	-8.84 %	-24.22 %
Seq. Cash & cash equivalent Change	-21.58 %	-51.96 %	-15.9 %	855.26 %	80.53 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 23
Healthcare Sector	# 644
Overall Market	# 1899

Quick Ratio Statistics
High	Average	Low
12.27	3.3	0.1
(Mar 31 2023)		(Dec 31 2021)

Financial Statements
Bioaffinity Technologies Inc 's Current Liabilities	$ 3 Millions	Visit BIAF's Balance sheet
Bioaffinity Technologies Inc 's Cash & cash equivalent	$ 2 Millions	Visit BIAF's Balance sheet
Source of BIAF's Sales		Visit BIAF's Sales by Geography

Cumulative Bioaffinity Technologies Inc 's Quick Ratio

BIAF's Quick Ratio for the trailling 12 Months

BIAF Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-4.04 %	-2.63 %	16.25 %	29.78 %	39.68 %
Y / Y Cash & cash equivalent TTM Growth	531.86 %	479.82 %	200.34 %	46.68 %	-70.63 %
Quick Ratio TTM	1.76	1.63	1.36	0.87	0.27
Total Ranking TTM	# 3926	# 2715	# 2953	# 2924	# 3087
Seq. Current Liabilities TTM Growth	0.84 %	-2.04 %	-1.73 %	-1.13 %	2.31 %
Seq. Cash & cash equivalent TTM Growth	9.03 %	17.27 %	53.33 %	222.31 %	0.05 %

Quick ratio ranking by company, industry and sector >> Back to BIAF Financial Strength Comparisons >> Go to Compare BIAF Quick Ratio to its Competitors

On the trailing twelve months basis BIAF Cash & cash equivalent more than doubled by 202.64 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Bioaffinity Technologies Inc 's Quick Ratio to 1.76, Quick Ratio remained below BIAF average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 35 other companies have achieved higher Quick Ratio than Bioaffinity Technologies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2715 to 3926.

Explain Quick Ratio?
How much Cash & cash equivalents BIAF�s has?
What are BIAF�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 36
Healthcare Sector	# 892
Within the Market	# 3926

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.29	2.93	0.27
(Jun 30 2023)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions
Natera Inc	1.97	$ 1,091.502 Millions	$ 553.200 Millions
Biodesix Inc	1.96	$ 29.996 Millions	$ 15.291 Millions
Sera Prognostics Inc	1.91	$ 46.445 Millions	$ 24.356 Millions
Exagen Inc	1.83	$ 24.588 Millions	$ 13.457 Millions
Radnet Inc	1.11	$ 773.510 Millions	$ 697.822 Millions
Bioaffinity Technologies Inc	0.91	$ 2.430 Millions	$ 2.681 Millions
Ispecimen inc	0.43	$ 4.426 Millions	$ 10.196 Millions
Quest Diagnostics Inc	0.40	$ 720.000 Millions	$ 1,788.000 Millions
Lumexa Imaging Holdings Inc	0.39	$ 69.705 Millions	$ 178.355 Millions
Medpace Holdings Inc	0.35	$ 502.688 Millions	$ 1,435.429 Millions
American Shared Hospital Services	0.30	$ 6.761 Millions	$ 22.424 Millions
Nuo Therapeutics, Inc.	0.29	$ 0.449 Millions	$ 1.554 Millions
Icon Plc	0.24	$ 930.885 Millions	$ 3,934.665 Millions

Date modified: 2026-09-12T06:26:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.